Reporting owner · CIK 0001178579

Tang Kevin

SEC Form 4 history for the last 180 days across 1 company, 14 transactions and 6 filings.

10%Boundless Bio, Inc.
Open-market transaction mix93% buys13 buys · 1 sale

Period: Last 180 days

Trade dates in this period: Aug 26, 2026 – Nov 10, 2026

Transaction history, summary figures and purchase returns cover the last 180 days. Earlier activity is excluded from those sections.

Filings6Form 4 records
Buying$458k13 purchases
Selling$54.4k1 sale
Net value+$404kBuys minus sells · disclosed values

Latest insider transactions

Form 4 filings from the last 180 days.
Tang Kevin transactions · 20 per page
CompanyActivityDisclosed valueFiled (ET)
BOLDBoundless Bio, Inc.
10% owner
10%
Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
SEC filing ↗
$598View disclosure →
BOLDBoundless Bio, Inc.
10% owner
10%
Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
SEC filing ↗
$4.08kView disclosure →
BOLDBoundless Bio, Inc.
10% owner
10%
Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
SEC filing ↗
$20.1kView disclosure →
BOLDBoundless Bio, Inc.
10% owner
10%
Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
SEC filing ↗
$1.24kView disclosure →
BOLDBoundless Bio, Inc.
10% owner
10%
Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
SEC filing ↗
$5.41kView disclosure →
BOLDBoundless Bio, Inc.
10% owner
10%
Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
SEC filing ↗
$25.7kView disclosure →
BOLDBoundless Bio, Inc.
10% owner
10%
Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
SEC filing ↗
$22.9kView disclosure →
BOLDBoundless Bio, Inc.
10% owner
10%
Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
SEC filing ↗
$14.8kView disclosure →
BOLDBoundless Bio, Inc.
10% owner
10%
Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
SEC filing ↗
$13.9kView disclosure →
BOLDBoundless Bio, Inc.
10% owner
10%
Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
SEC filing ↗
$521View disclosure →
BOLDBoundless Bio, Inc.
10% owner
10%
Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
SEC filing ↗
$42.6kView disclosure →
BOLDBoundless Bio, Inc.
10% owner
10%
Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
SEC filing ↗
$29.9kView disclosure →
BOLDBoundless Bio, Inc.
10% owner
10%
Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
SEC filing ↗
$277kView disclosure →
BOLDBoundless Bio, Inc.
10% owner
10%
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
SEC filing ↗
−$54.4kView disclosure →

Latest Form 4 facts

Quick context from source filings

Latest open-market transaction

The insider reported a buy at Boundless Bio, Inc. on Nov 10, 2026 valued at $597.60.

Review SEC filing
Latest sale

The insider reported a sale at Boundless Bio, Inc. on Aug 26, 2026 valued at $54,351.

Review SEC filing

Monthly open-market activity

Last 3 reported months · purchases and sales

View exact monthly values
Monthly open-market source values
MonthPurchasesSalesBuy valueSale valueNet value
Aug 202601$0$54,351−$54,351
Oct 202680$426,908.97$0+$426,908.97
Nov 202650$31,466.40$0+$31,466.40

Net value is disclosed purchases minus sales, not profit. A dash means the value is unavailable.

Ownership and transaction size

Ownership and ticket size

Average P/S size$36.6k
Median P/S size$17.5k
Direct0
Indirect14
Nov 10, 2026buy

Filing-only signals

Deterministic matches in this insider's history

Open-market buy performance

90-day forward return on this insider's open-market purchases

90d forward
Forward return is not available yet

No purchases currently have the price observations needed for a 90-day return. This may reflect incomplete price coverage or purchases that have not reached the return window.

Disclosed ownership

How reported shareholdings evolved

Non-derivative shares held after reported transactions—not stock prices or a complete portfolio.

14 observations · Aug 26, 2026 – Nov 10, 2026. Window ends at the latest available report, not today.

Selected observation · Nov 10, 20263,035,567 shares reported
Inspect transaction
View exact observations and source transactions
Transaction dateShares held afterFiledSource
Aug 26, 20262,840,635Aug 28, 2026View transaction
Oct 16, 20262,958,820Oct 20, 2026View transaction
Oct 19, 20262,971,610Oct 20, 2026View transaction
Oct 19, 20262,989,889Oct 20, 2026View transaction
Oct 20, 20262,990,109Oct 20, 2026View transaction
Oct 22, 20262,995,909Oct 26, 2026View transaction
Oct 23, 20263,002,143Oct 26, 2026View transaction
Oct 26, 20263,011,749Oct 26, 2026View transaction
Oct 27, 20263,022,456Oct 29, 2026View transaction
Nov 3, 20263,024,711Nov 5, 2026View transaction
Nov 4, 20263,025,228Nov 5, 2026View transaction
Nov 5, 20263,033,618Nov 5, 2026View transaction
Nov 6, 20263,035,318Nov 10, 2026View transaction
Nov 10, 20263,035,567Nov 10, 2026View transaction

Securities and direct/indirect ownership contexts are kept separate and never summed. Joint filings may associate the same disclosed row with multiple owners. Unknown values are omitted, not treated as zero. Lines connect observations for readability; they do not establish holdings between filings, cost basis, or current ownership. Amendments and stock splits require reviewing the source.

Tang Kevin Insider Activity FAQ

SEC Form 4 context

Who is Tang Kevin?

Tang Kevin is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001178579.

Which companies has Tang Kevin reported transactions for?

Boundless Bio, Inc., Aurinia Pharmaceuticals Inc., Singular Genomics Systems, Inc.

When was Tang Kevin's latest insider buy?

The insider reported a buy at Boundless Bio, Inc. on Nov 10, 2026 valued at $597.60.

When was Tang Kevin's latest insider sale?

The insider reported a sale at Boundless Bio, Inc. on Aug 26, 2026 valued at $54,351.

Where can I see the original SEC filings?

Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.

Are performance metrics included?

The profile shows average and median 90-day stock returns after open-market purchases when price coverage is available. These are unadjusted stock returns, not realized trading gains. Win rates, benchmark-adjusted returns and conviction scores are not calculated.